Document is current

Documents that mention this clinical trial

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab
https://doi.org/10.1016/j.ophtha.2015.02.036

Neutralization of Vascular Endothelial Growth Factor Slows Progression of Retinal Nonperfusion in Patients with Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.03.021

Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2015.04.029

Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE
https://doi.org/10.1016/j.ophtha.2016.02.007

Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials
https://doi.org/10.1016/j.ophtha.2016.04.004

Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.05.012

Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy
https://doi.org/10.1016/j.ophtha.2014.08.048

Effects of Intravitreal Ranibizumab on Retinal Hard Exudate in Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.10.028

Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States
https://doi.org/10.1016/j.ophtha.2014.12.007

Vision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.07.008

Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension
https://doi.org/10.1136/bmjophth-2022-001007

Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
https://doi.org/10.1016/j.ophtha.2015.08.006

A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.07.002

Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
https://doi.org/10.1016/j.ophtha.2013.02.034

Ranibizumab-Induced Diabetic Retinopathy Improvement—Results from Patients at High Risk for Vision Loss in RIDE/RISE and Protocol S
https://doi.org/10.2337/db18-601-p

The RESTORE Study
https://doi.org/10.1016/j.ophtha.2011.01.031

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
https://doi.org/10.1136/bmjophth-2019-000335

The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2016.03.038

Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2011.12.039

Documents that mention this clinical trial

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab
https://doi.org/10.1016/j.ophtha.2015.02.036

Neutralization of Vascular Endothelial Growth Factor Slows Progression of Retinal Nonperfusion in Patients with Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.03.021

Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2015.04.029

Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE
https://doi.org/10.1016/j.ophtha.2016.02.007

Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials
https://doi.org/10.1016/j.ophtha.2016.04.004

Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.05.012

Long-term Effects of Therapy with Ranibizumab on Diabetic Retinopathy Severity and Baseline Risk Factors for Worsening Retinopathy
https://doi.org/10.1016/j.ophtha.2014.08.048

Effects of Intravitreal Ranibizumab on Retinal Hard Exudate in Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.10.028

Visual Impairment and Blindness Avoided with Ranibizumab in Hispanic and Non-Hispanic Whites with Diabetic Macular Edema in the United States
https://doi.org/10.1016/j.ophtha.2014.12.007

Vision-Related Function after Ranibizumab Treatment for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.07.008

Effect of less aggressive treatment on diabetic retinopathy severity scale scores: analyses of the RIDE and RISE open-label extension
https://doi.org/10.1136/bmjophth-2022-001007

Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy
https://doi.org/10.1016/j.ophtha.2015.08.006

A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2014.07.002

Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
https://doi.org/10.1016/j.ophtha.2013.02.034

Ranibizumab-Induced Diabetic Retinopathy Improvement—Results from Patients at High Risk for Vision Loss in RIDE/RISE and Protocol S
https://doi.org/10.2337/db18-601-p

The RESTORE Study
https://doi.org/10.1016/j.ophtha.2011.01.031

Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedema
https://doi.org/10.1136/bmjophth-2019-000335

The Impact of Systemic Factors on Clinical Response to Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2016.03.038

Ranibizumab for Diabetic Macular Edema
https://doi.org/10.1016/j.ophtha.2011.12.039